BLCO Q4 2025 Deep Dive: Dry Eye and Product Innovation Propel Growth, Margin Expansion in Focus
BLCO Q4 2025 Deep Dive: Dry Eye and Product Innovation Propel Growth, Margin Expansion in Focus
Bausch + Lomb’s (NYSE:BLCO) Q4 CY2025: Beats On Revenue
Bausch + Lomb’s (NYSE:BLCO) Q4 CY2025: Beats On Revenue
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance
Delivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter Fourth-Quarter 2025 Financial Results ...
Bausch + Lomb (BLCO) Q4 Earnings: What To Expect
Bausch + Lomb (BLCO) Q4 Earnings: What To Expect
3 Reasons to Sell BLCO and 1 Stock to Buy Instead
3 Reasons to Sell BLCO and 1 Stock to Buy Instead
1 Healthcare Stock to Research Further and 2 Facing Headwinds
1 Healthcare Stock to Research Further and 2 Facing Headwinds
3 Stocks Under $50 That Fall Short
3 Stocks Under $50 That Fall Short
3 Cash-Burning Stocks We’re Skeptical Of
3 Cash-Burning Stocks We’re Skeptical Of
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results...